Disc Medicine, Inc. is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for serious hematologic diseases. Headquartered in Watertown, Massachusetts, the company focuses on modulating fundamental biological pathways related to red blood cell formation and function, primarily targeting heme biosynthesis and iron homeostasis.
As a pre-revenue, clinical-stage company, Disc Medicine does not currently generate product revenue and relies on equity financing, debt, and strategic collaborations to fund its operations. The company's pipeline features several promising candidates. Its lead asset, bitopertin, is a GlyT1 inhibitor in late-stage clinical development for erythropoietic porphyrias (EPP and XLP) and Diamond-Blackfan anemia. Another key candidate, DISC-0974, is an anti-hemojuvelin (HJV) monoclonal antibody designed to suppress hepcidin production and increase serum iron levels, currently in Phase 2 trials for anemia associated with myelofibrosis and chronic kidney disease. Additionally, the company is advancing DISC-3405, an anti-TMPRSS6 monoclonal antibody aimed at inducing hepcidin production for the treatment of polycythemia vera and other iron overload disorders.
Disc Medicine operates primarily in the United States and utilizes a network of third-party contract development and manufacturing organizations (CDMOs) to produce its clinical materials. The company went public in December 2022 through a reverse merger with Gemini Therapeutics. Its competitive position is defined by its specialized focus on iron regulation and heme biology, aiming to provide disease-modifying treatments rather than merely addressing the symptoms of hematologic disorders.
